A comparison of controlled-release aminophylline (Phyllocontin Continus tablets) and sympathomimetic bronchodilators.
In a crossover trial on twenty-four patients with reversible airways obstruction the rise in FEV1 on Phyllocontin Continus tablets (15%) was comparable to that achieved with Alupent tablets (14%). The usage of inhaled salbutamol and frequency of attacks of wheeziness were both greater when the patients were taking Alupent tablets. In a second study the effect of Phyllocontin tablets and Ventolin tablets both in combination with inhaled Ventolin and alone were examined. It was found that on Phyllocontin tablets alone patients showed a similar improvement (22%) in FEV1 to Ventolin tablets alone (19%). When inhaled Ventolin was added to Phyllocontin tablets a further rise in FEV1 was seen but not when inhaled Ventolin was added to Ventolin tablets.
D000420:Albuterol / Q000627:therapeutic use*; D000628:Aminophylline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D005541:Forced Expiratory Volume; D006801:Humans; D009921:Metaproterenol / Q000009:adverse effects / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D000628:Aminophylline; D009921:Metaproterenol; D000420:Albuterol